Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Randomized, Double-Blind, Study Evaluating Efficacy/Safety/Tolerability of Meropenem-Vaborbactam Compared to Piperacillin/Tazobactam in Adult Patients With Complicated Urinary Tract Infections, Including Acute Pyelonephritis

NCT02166476 is registered in ClinicalTrials.gov with Melinta Therapeutics, Inc. as lead sponsor.

NCT NCT02166476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02166476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Randomized, Double-Blind, Study Evaluating Efficacy/Safety/Tolerability of Meropenem-Vaborbactam Compared to Piperacillin/Tazobactam in Adult Patients With Complicated Urinary Tract Infections, Including Acute Pyelonephritis
Lead sponsor
Melinta Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 20, 2014
Completion date
April 28, 2016
Enrollment
550 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

acute pyelonephritis, urinary tract infection complicated